The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
San Bernardino Urological Associates
San Bernardino, California, United States
Western Clinical Research, Inc.
Torrance, California, United States
Shands Hospital
Gainesville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Georgia Urology,PA Research Institute
Atlanta, Georgia, United States
University of Chicago, Section of Hematology/Oncology
Chicago, Illinois, United States
University of Illinois, Department of Urology
Chicago, Illinois, United States
Michiana Hematology/Oncology
South Bend, Indiana, United States
The Urologic Institute of New Orleans
Gretna, Louisiana, United States
...and 43 more locations